We are live on ! Find out more
GPP

Great Point Partners Portfolio holdings

AUM $435M
1-Year Est. Return 318.81%
This Fund
S&P 500
This Quarter Est. Return
+28.73%
1 Year Est. Return
+318.81%
3 Year Est. Return
+553.97%
5 Year Est. Return
+856.21%
10 Year Est. Return
+18,148.08%
AUM
$435M
AUM Growth
+$127M
Cap. Flow
+$84M
Cap. Flow %
19.31%
Top 10 Hldgs %
52.49%
Holding
50
New
21
Increased
8
Reduced
4
Closed
8

Top Buys

Rank Stock Value
1
ALMS
Alumis Inc
ALMS
+$21.4M
2
SLGL icon
Sol-Gel Technologies
SLGL
+$19.8M
3
DRUG
Bright Minds Biosciences
DRUG
+$17.7M
4
ANNX icon
Annexon
ANNX
+$14.1M
5
ZBIO
Zenas BioPharma
ZBIO
+$11.8M

Top Sells

Rank Stock Value
1
IRON icon
Disc Medicine
IRON
+$19.9M
2
RAPT
RAPT Therapeutics
RAPT
+$19.7M
3
SLNO
Soleno Therapeutics
SLNO
+$18.5M
4
DNTH icon
Dianthus Therapeutics
DNTH
+$14.4M
5
FULC icon
Fulcrum Therapeutics
FULC
+$9.05M

Sector Composition

Rank Sector Weight
1 Healthcare 93.83%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
APGE icon
1
Apogee Therapeutics
APGE
$10.2B
$31.5M 7.23%
374,000
– –
VOR icon
2
Vor Biopharma
VOR
$1.04B
$31.2M 7.18%
1,750,000
+379,893
+28% +$5.36M
ZURA icon
3
Zura Bio
ZURA
$497M
$25.1M 5.77%
4,215,930
+400,000
+10% +$2.42M
AMLX icon
4
Amylyx Pharmaceuticals
AMLX
$2.05B
$24.3M 5.59%
1,750,000
– –
IBRX icon
5
PUT
ImmunityBio
IBRX
$7.44B
$23M 5.29%
+3,000,800
New +$20.5M
NKTR icon
6
Nektar Therapeutics
NKTR
$2.39B
$22.8M 5.23%
316,453
+105,721
+50% +$6.02M
SLGL icon
7
Sol-Gel Technologies
SLGL
$268M
$21.7M 5%
+274,363
New +$19.8M
ALMS
8
Alumis Inc
ALMS
$3.57B
$18.9M 4.33%
+856,061
New +$21.4M
DRUG
9
Bright Minds Biosciences
DRUG
$700M
$16.1M 3.69%
+220,000
New +$17.7M
ANNX icon
10
Annexon
ANNX
$855M
$13.8M 3.18%
+2,500,000
New +$14.1M
KALV
11
DELISTED
KalVista Pharmaceuticals
KALV
$13.6M 3.12%
675,000
-10,632
-2% -$171K
IMVT icon
12
Immunovant
IMVT
$8.09B
$13.6M 3.11%
545,625
-204,375
-27% -$5.29M
JBIO
13
Jade Biosciences
JBIO
$1.22B
$13.6M 3.11%
964,462
+158,189
+20% +$2.29M
CTNM
14
Contineum Therapeutics
CTNM
$526M
$10.5M 2.4%
800,198
+198
+0% +$2.66K
ZBIO
15
Zenas BioPharma
ZBIO
$1.92B
$10.2M 2.35%
+524,066
New +$11.8M
NGNE icon
16
Neurogene
NGNE
$696M
$10.1M 2.32%
500,000
+150,000
+43% +$2.91M
MLTX icon
17
MoonLake Immunotherapeutics
MLTX
$1.59B
$9.32M 2.14%
+500,000
New +$8.28M
CLYM
18
Climb Bio
CLYM
$735M
$9.14M 2.1%
1,334,130
+354,596
+36% +$2.05M
ORKA
19
Oruka Therapeutics
ORKA
$5.56B
$8.99M 2.07%
183,330
– –
EPRX
20
Eupraxia Pharmaceuticals
EPRX
$380M
$8.69M 2%
1,200,000
– –
VERA icon
21
Vera Therapeutics
VERA
$2.54B
$8.02M 1.84%
+199,348
New +$8.59M
EVMN
22
Evommune Inc
EVMN
$409M
$7.47M 1.72%
325,000
– –
LBRX
23
LB Pharmaceuticals
LBRX
$1B
$7.4M 1.7%
+300,000
New +$6.92M
CMPX icon
24
Compass Therapeutics
CMPX
$373M
$7.14M 1.64%
+1,350,000
New +$7.79M
SCYX icon
25
SCYNEXIS
SCYX
$37M
$6.93M 1.59%
+944,293
New +$5.84M
1
2

Similar funds

GDS
Gimbel Daniel Scott $435M AUM 78.68% 1-Year Est. Return
JWM
JPL Wealth Management Highlands Ranch, Colorado $435M AUM 16.48% 1-Year Est. Return
SWG
Summit Wealth Group White River Junction, Vermont $436M AUM 13.96% 1-Year Est. Return
SCP
Seafarer Capital Partners Larkspur, California $436M AUM 42.05% 1-Year Est. Return
NF
Napier Financial Braintree, Massachusetts $436M AUM
VIM
VELA Investment Management New Albany, Ohio $436M AUM 15.16% 1-Year Est. Return
VDBMI
Van Den Berg Management I Austin, Texas $436M AUM 40.66% 1-Year Est. Return
ACG
Anchorage Capital Group New York $436M AUM 38.51% 1-Year Est. Return

Great Point Partners's Q1 2026 Portfolio in Review

As of Q1 2026, Great Point Partners held 50 positions worth $435M, up 41% from $308M the previous quarter. Its ten largest holdings account for 52% of the portfolio.

Great Point Partners deployed $84M of net new capital in Q1 2026, opening 21 new positions and adding to 8 existing holdings. Its largest new stake was Alumis Inc: 856,061 shares worth $18.9M.

By sector, the portfolio is most concentrated in Healthcare at 94% of assets, down from 100% a quarter earlier.

On the sell side, the largest reduction was Context Therapeutics, an estimated $5.71M trimmed.

  • Great Point Partners's largest Q1 2026 buy was Alumis Inc: 856,061 shares worth $18.9M.
  • Great Point Partners added most to Nektar Therapeutics in Q1 2026, an estimated $6.02M increase.
  • Great Point Partners's biggest Q1 2026 reduction was Context Therapeutics, cutting an estimated $5.71M.
  • Great Point Partners fully exited Disc Medicine in Q1 2026, selling an estimated $19.9M.
  • Great Point Partners's ten largest holdings make up 52% of its $435M portfolio in Q1 2026.
  • Great Point Partners opened 21 new positions and closed 8 in Q1 2026.
  • Great Point Partners's portfolio value rose 41% quarter-over-quarter to $435M.

Based on Great Point Partners's 13F filing for Q1 2026, filed 15 May 2026.